Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

被引：0
|
作者：
Lewis-Wolfson, Temeka Dawn [1 ]
Joyner, Kayla Rena [2 ,3 ]
机构：
[1] Winchester Med Ctr, Pharm Dept, Winchester, VA 22601 USA
[2] Shenandoah Univ, Bernard J Dunn Sch Pharm, Dept Pharm Practice, Winchester, VA USA
[3] Winchester Med Ctr, Trauma & Acute Care Surg, Winchester, VA USA
来源：
ANNALS OF PHARMACOTHERAPY | 2023年 / 57卷 / 09期
关键词：
D O I：
10.1177/10600280221144936
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1118 / 1119
页数：2
相关论文
共 50 条
  • [21] Risk of hepatitis B reactivation following treatment with baricitinib or tocilizumab for COVID-19
    Foo, H.
    Phan, F.
    Bagatella, M.
    Acharya, P.
    Petrovski, I.
    Nagendra, V.
    Levy, M.
    Prakoso, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 71 - 72
  • [22] Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
    Gavriilidis, Efstratios
    Antoniadou, Christina
    Chrysanthopoulou, Akrivi
    Ntinopoulou, Maria
    Smyrlis, Andreas
    Fotiadou, Iliana
    Zioga, Nikoleta
    Kogias, Dionysios
    Natsi, Anastasia-Maria
    Pelekoudas, Christos
    Satiridou, Evangelia
    Bakola, Stefania-Aspasia
    Papagoras, Charalampos
    Mitroulis, Ioannis
    Peichamperis, Paschalis
    Mikroulis, Dimitrios
    Papadopoulos, Vasileios
    Skendros, Panagiotis
    Ritis, Konstantinos
    CLINICAL IMMUNOLOGY, 2022, 238
  • [23] Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
    Wang, Yong
    Chen, Yongfeng
    Zhou, Xiangdong
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2022, 2022
  • [24] Effective treatment of severe COVID-19 patients with tocilizumab
    Xu, Xiaoling
    Han, Mingfeng
    Li, Tiantian
    Sun, Wei
    Wang, Dongsheng
    Fu, Binqing
    Zhou, Yonggang
    Zheng, Xiaohu
    Yang, Yun
    Li, Xiuyong
    Zhang, Xiaohua
    Pan, Aijun
    Wei, Haiming
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (20) : 10970 - 10975
  • [25] Efficacy of Tocilizumab For Treatment of Severe COVID-19 Pneumonia: More Evidence Is Needed Reply
    Jordan, Stanley C.
    Huang, Edmund
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : E272 - E273
  • [26] Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study
    You, Seung-Hun
    Baek, Moon Seong
    Kim, Tae Wan
    Jung, Sun-Young
    Kim, Won-Young
    CRITICAL CARE, 2024, 28 (01)
  • [27] Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study
    Conroy, Grace M.
    Bauer, Seth R.
    Pallotta, Andrea M.
    Duggal, Abhijit
    Wang, Lu
    Sacha, Gretchen L.
    PHARMACOTHERAPY, 2024, 44 (01): : 28 - 38
  • [28] Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
    Aomar-Millan, Ismael F.
    Salcaterra, Juan
    Alvarez, Enrique Raya
    MEDICINA CLINICA, 2022, 159 (08): : E54 - E54
  • [29] Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
    Cardona-Pascual, Ignacio
    Berlana, David
    Martinez-Valle, Ferran
    Campany-Herrero, David
    Bruno Montoro-Ronsano, Jose
    MEDICINA CLINICA, 2022, 158 (07): : 301 - 307
  • [30] Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
    Kojima, Yuichi
    Nakakubo, Sho
    Takei, Nozomu
    Kamada, Keisuke
    Yamashita, Yu
    Nakamura, Junichi
    Matsumoto, Munehiro
    Horii, Hiroshi
    Sato, Kazuki
    Shima, Hideki
    Suzuki, Masaru
    Konno, Satoshi
    MEDICINA-LITHUANIA, 2022, 58 (04):
12345